Overall verdict
Buy
6.9/10
1-year performance
+53.35%
Score breakdown
Up 53.3% over 1 year, 78% of the 52-week range.
Strongest: Profitability 8.4/10. Weakest: Shareholder return 3.1/10.
30 analysts, target +0.1% vs the price.
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes ;
Jardiance, Mounjaro, and Trulicity for type 2 diabetes ; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma ; Erbitux for colorectal cancers and head and neck cancers ; Inluriyo for breast cancer ; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma ; Retevmo for the treatment of metastatic NSCLC ;
TYVYT for classic hodgkin's lymphoma ; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F.
Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss ; and Chugai Pharmaceutical Co., Ltd for orforglipron ; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases ; BioArctic AB (publ) for new treatment ; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system ; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Sector
Health Care
Industry
Pharmaceuticals
Primary listing
Nyse
United States
CEO
David Ricks
Founded
1876
Employees
50 000
Revenue / employee
1.3M USD
Next earnings
October 29, 2026 (Q3 2026)
Institutional holders
- LILLY ENDOWMENT INC9.71%
- BlackRock, Inc.7.26%
- VANGUARD CAPITAL MANAGEMENT LLC5.75%
- PNC Financial Services Group, Inc.5.50%
- STATE STREET CORP3.89%
- FMR LLC3.06%
- Capital Research Global Investors2.24%
- VANGUARD PORTFOLIO MANAGEMENT LLC2.24%
- GEODE CAPITAL MANAGEMENT, LLC2.18%
- Other institutions42.77%
- Rest of the register15.39%
4609 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
1292.65 USD
52-week low
712.05 USD
1-year performance
53.35%
Rising
Year-to-date performance
6.93%
Rising
Drawdown
-9.90%
Mild pullback
Position in the 52-week range
78% of range
Against the world ETF
Over 17 years, from September 2009 to August 2026, the share did better than the world ETF once risk is accounted for.
10,000 € placed at the end of September 2009 are worth today
| Eli Lilly and | 684 129 € |
| World ETF | 74 620 € |
| S&P 500 | 123 025 € |
| Risk-free placement | 11 288 € |
The risk
- Shaking:the share moves 2.0 times as much as the world ETF.
- Worst fall:-39 % between March 2025 and August 2025. 10,000 € placed at the top fell to 6 070 €. The world ETF, at worst: -34 %. Back to its high in 3 months.
Eli Lilly and earned 9 times as much as the world ETF since 2009
Value of 10,000 euros placed at the end of September 2009, dividends reinvested, in euros
- Eli Lilly and: 684 129 €
- World ETF: 74 620 €
- S&P 500: 123 025 €
- Risk-free placement: 11 288 €
Based on past performance. This is not a recommendation.
Range: 666.13 USD - 678.13 USD (2 methods agree)
The price implies growth of 19.35% per year; the company grows at 25.00%.
Gross margin 83.4%, net margin 33.5%, ROIC 39.8%, ROE 102.4%.
Net margin
33.53%
Exceptional
Sector 9.43%|S&P 12.97%
Gross margin
83.40%
Exceptional
Return on equity (ROE)
102.43%
Exceptional
Sector 6.16%|S&P 16.52%
Return on invested capital (ROIC)
39.81%
Exceptional
Free cash flow margin (FCF)
22.83%
Exceptional
Profit-to-cash conversion (FCF conversion)
0.68x
Fair
Margin stability
10.1 pts
Very uneven
Revenue to net income
Growth
7.3/10Revenue up 47.7% over 1 year, 21.6% a year over 5, EPS 27.6% a year over 5.
Revenue (trailing 12 months)
79.7Md USD
Revenue growth (1y)
47.67%
Hyper-growth
Revenue growth (3y)
128.37%
Hyper-growth
EPS growth (1y)
26.19%
Hyper-growth
EPS CAGR (5y)
27.59%
Exceptional
EPS revisions (3 months)
1.90%
Revised up
Valuation
3.5/10P/E 39.6x, forward P/E 33.1x, EV/EBITDA 26.8x, PEG 1.43. The multiple sits in the 36th percentile of its own 5-year history.
P/E (TTM)
39.6x
Expensive
Sector 27.3x|S&P 23.0x
Forward P/E
33.1x
Very expensive
EV / EBITDA
26.8x
Expensive
Sector 16.0x|S&P 14.5x
PEG
1.43
Fair
Sector 1.05|S&P 0.86
Fair value (reverse DCF)
672.13 USD
Deeply overvalued
P/E vs its own 5-year history
among the 36% lowest valuations
Cheaper than usual
Market cap
1.1T USD
Financial strength
6.2/10Cash covers 16.3% of the debt, net debt/EBITDA 1.2x.
Net debt / EBITDA
1.2x
Solid
Gearing (net debt / equity)
135.65%
Stretched
Cash
8.9Md USD
Cash / market cap
0.83%
Stretched
Cash / total debt
16.30%
Tight
Net debt
46.0Md USD
Equity
33.9Md USD
Closed daily candles, 2 years
Last close on September 24, 2026: 1,181.89 USD
- MM201,150.44
- MM501,177.13
- MM2001,069.16
- RSI 1455.3
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+1.23%
200-day average slope, 3 months
+9.81%
50-day average slope, 1 month
-0.52%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
1.16 % per day
Volatility change
-45.89%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 35.17 (11) | 36.91 (27) | 88 428 (28) | 43 514 (15) | 31 565 (8) |
| 2027 | 44.49 (11) | 47.54 (27) | 102 103 (28) | 54 009 (15) | 39 769 (8) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 22, 2026.
Same sub-industry: 509 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | BMY | 7.2 | 7.8 | 125Md USD | 13.5x | 18.9 % | 5.8 % | 14.3 % | 1.9x | 9.2 % | 37.4 % | ||
| 2 | LLY | 6.9 | 5.8 | 1.1T USD | 39.6x | 33.5 % | 47.7 % | 39.8 % | 1.2x | 1.7 % | 53.3 % | ||
| 3 | NOVO B | 6.6 | 7.4 | 170Md USD | 9.5x | 35.3 % | 2.1 % | 38.9 % | 0.7x | 6.7 % | -32.6 % | ||
| 4 | NOVN | 6.3 | 6.2 | 261Md USD | 22.6x | 23.3 % | -2.0 % | 17.2 % | 1.0x | 6.3 % | 22.0 % | ||
| 5 | JNJ | 6.2 | 5.7 | 649Md USD | 31.2x | 21.5 % | 6.6 % | 17.5 % | 0.9x | 3.4 % | 53.7 % | ||
| 6 | ROP | 6.1 | 5.7 | 352Md USD | 23.7x | 20.3 % | 1.7 % | 21.8 % | 0.8x | 5.2 % | 35.9 % | ||
| 7 | AZN | 5.8 | 6.5 | 255Md USD | 24.8x | 17.0 % | 5.8 % | 14.3 % | 1.2x | 4.2 % | 10.7 % | ||
| 8 | MRK | 5.0 | 4.4 | 365Md USD | 118.4x | 4.8 % | 4.9 % | 3.6 % | 1.2x | 4.4 % | 85.2 % | ||
| 9 | PFE | 4.9 | 4.6 | 161Md USD | 37.3x | 6.8 % | 2.6 % | 3.0 % | 2.3x | 6.8 % | 17.5 % |
